Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841756 | 1.00 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL841069 | 0.91 | NR1I2 (0.52) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL10272117 | 0.90 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL842095 | 0.90 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862724 | 0.90 | KCNH2 (0.53) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL863116 | 0.90 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862983 | 0.90 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL842239 | 0.89 | KCNH2 (0.51) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL277742 | 0.89 | KCNH2 (0.50) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL841686 | 0.88 | KCNH2 (0.61) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |